Sheila Blalock
Nurse Practitioner · Crossville, TNNPI 1952625030
Payments from drug & device makers
Across 639 payments — averaging $14.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$1K
- GSK$1K
- Pfizer$827
- Lilly USA, LLC$825
- AstraZeneca$544
- plus $3K from 32 others
What the payments were for
- Food & beverage$9,238100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 153 | $1,884 |
| Novo Nordisk | 80 | $1,188 |
| GSK | 71 | $1,022 |
| Pfizer | 69 | $827 |
| Lilly USA, LLC | 70 | $825 |
| AstraZeneca(2 entities) | 27 | $544 |
| Amgen(2 entities) | 22 | $355 |
| Corcept Therapeutics | 17 | $344 |
| Axsome Therapeutics, Inc. | 16 | $287 |
| Lundbeck LLC | 7 | $178 |
| Boehringer Ingelheim | 11 | $173 |
| Bayer | 10 | $154 |
| Merck | 9 | $137 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $131 |
| Xeris Pharmaceuticals, Inc. | 6 | $115 |
| Antares Pharma, Inc. | 5 | $111 |
| Otsuka America Pharmaceutical, Inc. | 6 | $100 |
| Sanofi-aventis U.S. LLC | 6 | $94 |
| Phathom Pharmaceuticals, Inc. | 7 | $86 |
| Ultragenyx Pharmaceutical Inc. | 3 | $70 |
| Abbott | 3 | $65 |
| Novartis | 3 | $61 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $61 |
| Johnson & Johnson | 3 | $58 |
| Amarin Pharma, Inc. | 4 | $53 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $43 |
| Esperion Therapeutics, Inc. | 2 | $39 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $33 |
| Exact Sciences | 2 | $28 |
| Bausch Health US, LLC | 2 | $26 |
| Idorsia Pharmaceuticals US Inc | 1 | $24 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
| Halozyme Inc | 1 | $22 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $20 |
| Organon | 1 | $17 |
| Impel Pharmaceuticals Inc. | 1 | $16 |
| Phadia US Inc. | 1 | $14 |
| Eisai Inc. | 1 | $13 |
How this compares
$9,238 in reported general payments places this provider in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 107 | $155,881 |
| JardianceEmpagliflozin | 69 | $81,310 |
| EliquisApixaban | 53 | $62,012 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 71 | $61,842 |
| VraylarCariprazine Hcl | 43 | $60,502 |
| LinzessLinaclotide | 39 | $36,826 |
| TrintellixVortioxetine Hydrobromide | 43 | $28,340 |
| TrulicityDulaglutide | 16 | $27,989 |
| OzempicSemaglutide | 27 | $24,678 |
| GlyxambiEmpagliflozin/Linagliptin | 17 | $22,302 |
| MyrbetriqMirabegron | 24 | $20,814 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 19 | $18,830 |
| Emgality PenGalcanezumab-Gnlm | 25 | $16,860 |
| Repatha SureclickEvolocumab | 15 | $15,609 |
| XareltoRivaroxaban | 18 | $14,074 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $825 | $183,870123 claims |
| Boehringer IngelheimJardiance, Glyxambi, Synjardy Xr, Trijardy Xr, Tradjenta | $173 | $135,643129 claims |
| AbbVieVraylar, Linzess, Creon, Qulipta | $1,884 | $123,637106 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $1,022 | $75,24983 claims |
| PfizerEliquis | $827 | $62,01253 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $131 | $28,34043 claims |
| Novo NordiskOzempic | $1,188 | $24,67827 claims |
| Johnson & JohnsonXarelto | $58 | $14,07418 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $100 | $13,41812 claims |
| AstraZenecaFarxiga | $544 | $11,14716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.
Other nurse practitioner in Crossville
- Amy HatcherMurfreesboro$1.1M
- Karen RodenKnoxville$265K
- Susan UtleyNashville$194K
- Whitney EricksonMemphis$159K
- Erica HembreeKnoxville$125K
- Brooke FaughtNashville$89K
- Lauren WelchNashville$71K
- Cara StoutKingsport$71K
- S Marie HamiltonOoltewah$64K
- Cynthia WilsonChattanooga$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.